{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:07:39Z","timestamp":1779394059557,"version":"3.53.1"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tenofovir alafenamide (TAF) was introduced in the European Union in 2015 as a novel prodrug of tenofovir showing similar efficacy in clinical trials and a more favorable safety profile than tenofovir disoproxil fumarate (TDF). The German TAFNES cohort study (2016\u20132019) was conducted to generate real\u2010world evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Treatment\u2010na\u00efve (TN) and treatment\u2010experienced (TE) people with HIV (PWH) receiving elvitegravir\/cobicistat\/emtricitabine\/TAF (E\/C\/F\/TAF), rilpivirine\/F\/TAF (R\/F\/TAF) or F\/TAF\u2009+\u20093rd agent were included. Month (M) 24 outcomes included virologic effectiveness (HIV RNA &lt;50 copies\/mL), treatment persistence, adverse drug reactions (ADRs) and patient\u2010reported outcomes, using the HIV Symptom Index (HIV\u2010SI), 36\u2010Item Short Form Health Survey (SF\u201036) and HIV Treatment Satisfaction (HIVTSQ) questionnaires.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 767 PWH (92% men, median age 46\u2009years; 301 TN, 466 TE; E\/C\/F\/TAF [<jats:italic>n<\/jats:italic>\u2009=\u2009318], R\/F\/TAF [<jats:italic>n<\/jats:italic>\u2009=\u2009192], F\/TAF\u2009+\u20093rd agent [<jats:italic>n<\/jats:italic>\u2009=\u2009257]). Among TN, 35% had late HIV diagnosis (CD4\u2009&lt;\u2009350\/\u03bcL and\/or AIDS). Of TE, 95% were on suppressive antiretroviral therapy (ART) before switching. D:A:D (Data Collection on Adverse Effects of Anti\u2010HIV Drugs) 5\u2010year risks for chronic kidney disease were high for about 1 in 10 TN and 4 in 10 TE. Overall treatment persistence at M24 was 81% (E\/C\/F\/TAF: 88%; R\/F\/TAF: 86%; F\/TAF\u2009+\u20093rd agent: 70%, with ART simplification of multiple\u2010tablet regimens in 13%). M24 viral suppression (missing\u2009=\u2009excluded) was 96% (479\/501). Discontinuations due to virologic failure or ADRs were rare, 2% (12\/767) and 4% (30\/767), respectively. HIV\u2010SI and SF\u201036 summary scores improved in TN; HIVTSQ change scores showed an improvement in treatment satisfaction in TE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Real\u2010world data confirmed a favorable safety profile and high virologic effectiveness with high treatment satisfaction on F\/TAF\u2010based ART.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13728","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T23:01:21Z","timestamp":1730329281000},"page":"239-251","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness, safety, and patient\u2010reported outcomes of emtricitabine\/tenofovir alafenamide\u2010based regimens for the treatment of <scp>HIV<\/scp>\u20101 infection: Final 24\u2010month results from the prospective <scp>German TAFNES<\/scp> cohort study"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3777-9006","authenticated-orcid":false,"given":"Christoph","family":"Stephan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 2, Infectious Diseases Unit, University Hospital Goethe University Frankfurt  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[{"name":"TUM School of Medicine and Health, Department of Clinical Medicine \u2013 Clinical Department for Internal Medicine II, University Medical Center Technical University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Rieke","sequence":"additional","affiliation":[{"name":"Gemeinschaftsklinikum Mittelrhein, Kemperhof  Koblenz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Christensen","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases (CIM)  M\u00fcnster Germany"},{"name":"Department of Gastroenterology, Hepatology and Infectious Diseases University Hospital Muenster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[{"name":"Center for HIV and Hepatogastroenterology  Dusseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Gilead Sciences GmbH  Martinsried Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"Gilead Sciences GmbH  Martinsried Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Heinzkill","sequence":"additional","affiliation":[{"name":"Gilead Sciences GmbH  Martinsried Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Ramroth","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010J\u00fcrgen","family":"Stellbrink","sequence":"additional","affiliation":[{"name":"ICH Study Center  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00024-2"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000618"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30031-0"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30179-0"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000940"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0203"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30195-X"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_2_13_11_1","unstructured":"MedDRA \u2013 Medical Dictionary for Regulatory Activities.2022. (Accessed March 8 2024 athttps:\/\/www.ich.org\/page\/meddra.)"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_13_13_1","first-page":"155A","article-title":"A simplified equation to predict glomerular filtration rate from serum creatinine","volume":"11","author":"Levey AS","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001809"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00449-8"},{"key":"e_1_2_13_16_1","volume-title":"SF\u201036 Fragebogen zum Gesundheitszustand","author":"Morfeld M","year":"2011"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03404342"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00121.x"},{"key":"e_1_2_13_19_1","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"Centers for Disease Control and Prevention","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_13_20_1","first-page":"199","article-title":"Renal tubular transporter\u2010mediated interactions of HIV drugs: implications for patient management","volume":"16","author":"Guti\u00e9rrez F","year":"2014","journal-title":"AIDS Rev"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30032-2"},{"key":"e_1_2_13_22_1","unstructured":"Genvoya Summary of Product Information.2021. (Accessed March 8 2024 athttps:\/\/www.ema.europa.eu\/en\/documents\/product-information\/genvoya-epar-product-information_en.pdf.)"},{"key":"e_1_2_13_23_1","unstructured":"Odefsey Summary of Product Characteristics.2021. (Accessed March 8 2024 athttps:\/\/www.ema.europa.eu\/en\/documents\/product-information\/odefsey-epar-product-information_en.pdf.)"},{"key":"e_1_2_13_24_1","volume-title":"Sch\u00e4tzung der Zahl der HIV\u2010Neuinfektionen und der Gesamtzahl von Menschen mit HIV in Deutschland, Stand Ende 2017","year":"2018"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001817"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30021-3"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002223"},{"key":"e_1_2_13_32_1","unstructured":"European AIDS Clinical Society (EACS) Guidelines 12.0.2023. (Accessed March 8 2024 athttps:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf)"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0640-4"},{"key":"e_1_2_13_34_1","first-page":"28","volume-title":"High levels of patient satisfaction during rapidly initiated therapy with darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) for treatment of HIV\u20101 infection through 24\u2009weeks of the DIAMOND study [PO49]","author":"Benson C","year":"2018"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1213"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S332555"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0322-8"},{"key":"e_1_2_13_38_1","volume-title":"2\u2010Year outcomes of dolutegravir (DTG) and lamivudine (3TC) in art\u2010naive and pre\u2010treated people living with HIV in Germany: real\u2010world data from the German URBAN Cohort [P117]","author":"Beer DS","year":"2022"},{"key":"e_1_2_13_39_1","volume-title":"Poster presented at HIV Drug Therapy Glasgow","author":"Schabaz FS"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:21:11Z","timestamp":1738416071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/hiv.13728"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13728","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"2024-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}